Global Diabetes Drugs and Devices Market Analysis: Oral, Injectable, Non-Injectable Drugs, Diagnostics and Forecast to 2020

The global diabetes drugs and devices market is estimated to exceed USD 85 Billion in 2020, expanding at a CAGR of 4.4% from 2016 to 2020, due to rising diabetic population and associated diseases worldwide.

Browse Diabetes Drugs and Devices Market by The Drug Type (Insulin Derivatives – Short-Acting, Intermediate-Acting, Long-Acting, Premixed, and Rapid-Acting Insulin; Oral Anti-Diabetes Drugs – Alpha-Glucosidase Inhibitors, Biguanides, DPP-4 Inhibitors, Meglitinides, SGLT-2 Inhibitors, Sulphonylureas, Thiazolidinediones; and Non-Insulin Injectable Anti-Diabetes Drugs – GLP-1 Analogs), Device Type (Diabetes Monitoring and Diagnostic Devices – Analog Glucose Meter, Continuous Glucose Monitoring Devices, Glucose Test Strips, Lancets and Lancing Devices; Insulin Delivery Devices – Insulin Injectors, Pens, Pumps, Syringes) 2016-2020 at https://www.ihealthcareanalyst.com/report/diabetes-drugs-devices-market/

The elevated sugar level leads to various symptoms such as increased thirst, weight loss, high appetite, frequent and sweet smelled urination. If untreated, diabetes causes various acute and chronic life-threatening complications.
The type of diabetes determines either blood sugar monitoring, insulin or oral medications as a treatment. Treatment for type 1 diabetes involves insulin injections or the use of an insulin pump, frequent blood sugar checks, and carbohydrate counting. Treatment of type 2 diabetes primarily involves monitoring of your blood sugar, along with diabetes medications, insulin or both.

The global diabetes drugs and devices market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (insulin derivatives - short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs - alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs - GLP-1 analogs), device type (diabetes monitoring and diagnostic devices - analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices - insulin injectors, pens, pumps, syringes, etc.), and forecasts growth trends (CAGR% - 2016 to 2020). The global diabetes drugs and devices market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global diabetes drugs and devices market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global diabetes drugs and devices market and included in this report are Abbott Laboratories, Inc., AstraZeneca plc, B Braun Melsungen AG, Bayer HealthCare AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, DexCom, Inc., Eli Lilly and Company, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Medtronic, Inc., Merck & Co., Inc., Novartis International AG, Novo Nordisk A/S, Sanofi, and Takeda Pharmaceutical Co. Ltd.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/diabetes-drugs-devices-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 500-7508
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.